In 1505 adults with moderate-to-severe plaque psoriasis in two phase III trials, oral icotrokinra gave durable skin clearance to week 52: about 70–75% reached IGA 0/1 or PASI 90 and about 50% IGA 0 or PASI 100 during weeks 24–52, with no safety signals.
RCTn = 1,505
Stein Gold et al. Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials